A viral over-expression system for the major malaria mosquito Anopheles gambiae

Yasutsugu Suzuki, Guodong Niu*, Grant L. Hughes & Jason L. Rasgon

Department of Entomology, Center for Infectious Disease Dynamics and the Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, Pennsylvania, 16802, United States of America.

Understanding pathogen/mosquito interactions is essential for developing novel strategies to control mosquito-borne diseases. Technical advances in reverse-genetics, such as RNA interference (RNAi), have facilitated elucidation of components of the mosquito immune system that are antagonistic to pathogen development, and host proteins essential for parasite development. Forward genetic approaches, however, are limited to generation of transgenic insects, and while powerful, mosquito transgenesis is a resource- and time-intensive technique that is not broadly available to most laboratories. The ability to easily “over-express” genes would enhance molecular studies in vector biology and expedite elucidation of pathogen-refractory genes without the need to make transgenic insects. We developed and characterized an efficient Anopheles gambiae densovirus (AgDNV) over-expression system for the major malaria vector Anopheles gambiae. High-levels of gene expression were detected at 3 days post-infection and increased over time, suggesting this is an effective system for gene induction. Strong expression was observed in the fat body and ovaries. We validated multiple short promoters for gene induction studies. Finally, we developed a polycistronic system to simultaneously express multiple genes of interest. This AgDNV-based toolset allows for consistent transduction of genes of interest and will be a powerful molecular tool for research in Anopheles gambiae mosquitoes.

Anopheles sp. are the only mosquitoes that transmit Plasmodium parasites to humans, and as such, are a major concern for public health1. Anopheles gambiae is the major vector of Plasmodium falciparum, the major cause of malaria in sub-Saharan Africa2. Issues with current control strategies such as the lack of effective vaccines and emergence of insecticide resistance3,4 necessitate the need for novel disease prevention measures. One such strategy is to control pathogen transmission by mosquitoes using transgenic technology. However, generation of transgenic Anopheles mosquitoes is technically challenging, and limited success has been reported in An. gambiae5-7. Alternative strategies such as the use of microbes to control pathogens are gaining considerable attention (reviewed in refs)8-9.

Paratransgenesis (genetic manipulation of symbiotic microorganisms to interfere with pathogen development in the host) has been proposed as a control strategy for vector-borne diseases10. Paratransgenic control approaches have several advantages over strategies based on insect transgenesis. Microorganisms help maintain host homeostasis can be tightly associated with their insect host. These microbes are often more straightforward to transform compared to the insect11, and microbes can often spread through insect populations12-15. As such, paratransgenic control strategies are being considered for a wide range of viral, bacterial and fungal microbes16-25. Paratransgenic approaches using bacteria and fungi have been shown to significantly reduce Plasmodium levels in An. gambiae18,20.

Pathogens within mosquitoes can also be inhibited by manipulating host genes essential for pathogen development26. To explore such gene functions, effective tools to manipulate the host are essential. However manipulating gene expression in Anopheles mosquitoes has been constrained because only a few techniques are available, mainly RNA interference (RNAi) and transgenic manipulation16,29-31. As such, the development of efficient and simple transient over-expression systems in mosquitoes will facilitate investigations on mosquito biology and applied mosquito-borne diseases control strategies.

Viral vector transduction is a common approach to over-express genes in many host systems (reviewed in refs)32-35. Viruses actively enter target cells, are effective in vitro and in vivo and can be modified for specific aims such as tissue tropism36,37. Densoviruses (DNVs) are non-enveloped single-stranded paroviruses that are widely...
distributed among arthropods including multiple mosquito species\textsuperscript{38–43}. *Aedes aegypti* densovirus (AeDNV) has been intensively studied as a transducing vector for *Aedes* mosquitoes\textsuperscript{44–47}. DNVs are often pathogenic to mosquitoes\textsuperscript{45,48}, and their pathogenicity can be improved by engineering\textsuperscript{46}. Previously, we isolated a DNV from *Anopheles gambiae* (AgDNV), showed that it replicates preferentially in adult mosquitoes, imparts minimal impact on host genes expression and is avirulent\textsuperscript{19,49,50}. Here we report on the development of an

**Figure 1** | New AgDNV transducing vector. (a) Schematic representation of recombinant AgDNV vectors. Both vectors consist of the viral terminal hairpins, UTR’s and EGFP gene driven by Actin5C promoter and SV40 terminator. vAgActinGFP lacks 27 bp of the 5’ UTR (referred to as ΔUTR) and contains a portion of the viral capsid gene (ΔVP). vUTRacGFP has the intact 5’ UTR and no viral capsid gene sequence. Each vector genome size relative to wild-type virus is indicated. (b) MOS55 cells were infected with equivalent titers of vAgActinGFP or vUTRacGFP. EGFP expression was visualized by fluorescence microscopy. (b) MOS55 cells were infected with equivalent titers of vAgActinGFP or vUTRacGFP. EGFP expression was visualized by fluorescence microscopy. (b) MOS55 cells were infected with equivalent titers of vAgActinGFP or vUTRacGFP. EGFP expression was visualized by fluorescence microscopy. (b) MOS55 cells were infected with equivalent titers of vAgActinGFP or vUTRacGFP. EGFP expression was visualized by fluorescence microscopy. (c) The mean fluorescence intensity (MFI) of EGFP was determined by flow cytometry. (d) Recombinant AgDNV replication in MOS55 cells. Supernatants from infected cells were collected from Days 0–3 post infection. Viral DNA was quantified by qPCR. Mean and standard deviation (S.D.) were calculated from three independent infections in (c) and (d). Treatments are significantly different (Student’s T test).
improved viral transduction system, which can efficiently overexpress multiple genes of interest in An. gambiae mosquitoes at high frequency.

**Results**

**Generation and evaluation of a new recombinant AgDNV vector.**

We use the prefix “v” to denote viral vectors and “p” to indicate their infectious plasmids. Our previous recombinant AgDNV harboring the EGFP gene, vAgActinGFP (derived from pAgActinGFP) is 4283 base pairs (bp) in length and is approximately 3.5% longer than the wild-type AgDNV genome19. In the course of working with this virus for several years, we noted that EGFP expression in An. gambiae adults infected with vAgActinGFP is highly variable (unpublished observation). The variation is possibly due to the large size of the viral genome. For other DNVs, efficient packaging of the viral genome is inhibited when the transducing genome was larger than the wild-type genome20. To shorten our recombinant AgDNV vector, we generated a new DNV vector plasmid (pUTR) which contained both hairpins and the entire AgDNV 5' and 3' untranslated regions without any ORFs from the wild-type AgDNV plasmid pBAg20. The Actin5C promoter-EGFP-SV40 terminator cassette was inserted into pUTR and a new transducing construct developed (pUTRAcGFP). vUTRAcGFP has a genome length of 4011 bp, which is 128 bp shorter than wild-type AgDNV genome (4139 bp). We compared transduction and replication efficiency between vUTRAcGFP and vAgActinGFP (Fig. 1a). To provide viral proteins for replication of recombinant viruses, all recombinant virus samples were prepared by co-transfection of pBAg (wild-type AgDNV plasmid) and recombinant virus plasmids. MOS55 cells were infected with equal titers of the vAgAcGFP or vUTRAcGFP. vUTRAcGFP-infected cells showed 3-fold higher intensity of EGFP than cells infected with vAgAcGFP (Fig. 1b and c). To compare the replication kinetics of each viral vector, supernatant was collected from the DNV-infected MOS55 cells at 0–3 days post infection and the encapsulated recombinant

---

Figure 2 | Transduction of An. gambiae with vUTRAcGFP by intrathoracic microinjection. EGFP expression was visualized by fluorescence microscopy. (a) An. gambiae adults were injected with 1 × 10^5, 10^6 or 10^7 particles of vUTRAcGFP and visualized at seven days post-injection. (b) Non-destructive time course of EGFP expression in the mosquitoes injected with 1 × 10^7 of vUTRAcGFP. (c) Tissue tropism of recombinant AgDNV. Fluorescence was observed in the fat body, ovaries, malpighian tubules and proboscis.
viral genome DNA enumerated by quantitative PCR (qPCR). The recombinant viral DNA of vAgActinGFP plateaued at approximately 2–2.5 × 10^5 genome copies per μl after two days. In comparison, vUTRAGFP showed over a 5-fold increase of 1.2 × 10^6 copies per μl at the same time point and had not yet plateaued (Fig. 1d).

High level and consistent transduction of AgDNV in An. gambiae mosquitoes. Next, we assessed the infectivity of vUTRAGFP in vivo. Recombinant virus and helper virus was intrathoracically injected into the thorax of adult female mosquitoes, with 10–20 mosquitoes per treatment. Adult mosquitoes were injected with 1 × 10^5, 10^6 or 10^7 vUTRAGFP and collected 7 days post injection to examine EGFP expression. Fluorescence was observed in all mosquitoes in a dose-dependent manner (Fig. 2a). We next conducted a virus replication time course experiment, repeatedly non-destructively examining the same mosquito at each time point. EGFP was visible beginning day two post-injection. Fluorescence increased throughout the experiment to 15 days post-injection (Fig. 2b). To determine the tissue tropism of vUTRAGFP, we dissected infected mosquitoes. The majority of EGFP expression was observed in the fat body and the ovary (Fig. 2c), but was also visible in other tissues including muscle, malpighian tubules and the proboscis (Fig. 2c). No significant fluorescence was observed in midgut or salivary glands (data not shown).

Comparison of 6 different promoter cassettes for recombinant AgDNV gene transduction. Parvoviral vectors have a size limitation for efficient genome packaging. In Aedes aegypti DNV-based vectors, genomes that exceed the wild-type size by more than 10% cannot be efficiently packaged51. pUTR with the Actin5C promoter cassette is 3291 bp in length, allowing for the insertion of genes less than 1000 bp. It would be desirable to shorten the promoter so that larger genes of interest can be expressed in this system. We assessed several shorter promoters by exchanging the Actin5C promoter in pUTRAGFP. All viruses were compared for their ability to transduce Anopheles gambiae both in vitro and in vivo. All recombinant DNV genomes contained the EGFP gene under the control of different promoters: vUTRp7, the native AgDNV non-structural promoter and polyadenylation sequence that exist in the UTR sequences; vUTR Copia, 247 bp copia promoter and 134 bp SV40 early polyadenylation signal (SV40E polyA); vUTR Ac2, 335 bp Actin5C promoter for exon2 and exon3^2 and SV40E polyA; vUTR Ex, 1082 bp Autographa californica nuclear polyhedrosis virus (AcNPV)-derived hr5 enhancer and immediate early promoter IE1 and 308 bp IE terminator; vURAcSh a 307 bp truncated version of the Actin5C promoter53 and SV40E polyA (Fig. 3). We evaluated activity of each promoter cassette in plasmid-transfected and virus-infected MOS55 cells (Fig. 4a). In plasmid-transfected cells, the IEx promoter showed the highest level of EGFP expression (Fig 4a). In pURAcGFP-transfected MOS55 cells, relatively high expression was observed (Fig 4a). Both of IEx and AcSh promoter cassettes showed higher expression of EGFP than the longest Actin5C promoter. In comparison, transduction experiments with virus demonstrated that vURAcGFP had higher transduction efficiency than vUTR ExGFP or vURAcShGFP (Fig. 4a). We quantified viral promoter efficiency using flow cytometry. Viruses driving EGFP from p7, copia or Ac2 showed very little fluorescence. In contrast, viruses containing the IEx, short actin or long actin promoters showed strong fluorescence. The Actin5C promoter had 21 times higher EGFP intensity than the p7 promoter (P < 0.00005) (Fig. 4b). IEx and AcSh promoters showed 4.4 and 4.1 times higher activity than p7 respectively (P < 0.005) (Fig. 4b). Next, we compared EGFP transduction in vivo. An. gambiae adults were injected with 5 × 10^8 of each of the recombinant DNVs and EGFP expression was visualized at day 7 post-injection. Similar to results in vitro, vURAcGFP-transduced mosquitoes showed the highest EGFP expression (Fig. 5). Although the intensities were lower than Actin5C, intermediate EGFP expression was observed in vUTR ExGFP- and vURAcShGFP-infected mosquitoes. No visible fluorescence was observed in the mosquitoes infected with vUTRp7GFP, vUTR CopiaGFP or vUTR Ac2GFP.

Development of a polycistronic AgDNV-based expression vector. vURAcGFP harbors the longest promoter-cassette and showed the...
highest expression of EGFP among the investigated AgDNV vectors. However, the smaller vUTRIExGFP and vUTRAcShGFP had intermediate expression activity in vitro and in vivo (Fig. 4 and 5). We chose the recombinant AgDNV containing the AcSh promoter as a backbone as it could accommodate up to 2.7 kb of cargo. To polycistronically express multiple open reading frames we used the *Thosea asigna* virus-derived 2A-like sequence54,55 to simultaneously express 3 genes; mCherry, EGFP and the AgDNV viral capsid protein (Fig. 6, vUTRAcShmCherry-GFP-VP). Western blot for EGFP confirmed that the 2A-like sequences were cleaved in mosquito cells (Fig. 7a, Supplementary Fig. 1). mCherry and EGFP fluorescence was visually observed in vUTRAcShmCherry-GFP-VP-infected MOS55 cells (Fig. 7b) and quantified using flow cytometry (Fig. 7c). The percentage and intensity of EGFP-positive cells were significantly higher than those infected with vUTRAcShGFP-infected cells (P < 0.005 and P < 0.0005 respectively) (Fig. 7d). *An. gambiae* adults were injected with 5 × 10^6 of each recombinant DNV. Both mCherry and EGFP fluorescence was detected in

---

Figure 4 | Comparison of expression promoter constructs in vitro. (a) EGFP expression visualized by microscopy in plasmid-transfected and DNV-infected MOS55 cells. 2.5 μg of plasmids and 5 × 10^8 of recombinant DNVs were used for transfection and infection experiments respectively. (b) EGFP intensity was quantified by a flow cytometry in each of the DNV-infected MOS55 cell cultures. Fold-changes in EGFP expression was compared to vUTRp7GFP-infected cells. Mean and S.D. were calculated from three independent infections. P-values were calculated by Student’s T test.
vUTRAcShmCherry-GFP-VP-infected mosquitoes (Fig. 8). Again, EGFP expression was higher in vUTRAcShmCherry-GFP-VP-infected compared to vUTRAcShGFP mosquitoes (Fig. 8) even though mosquitoes in both treatments were infected with the same amount of virus. Levels of expression could also be boosted in a dose-dependent manner (Fig. 8).

Discussion

Molecular tools to manipulate gene expression have drastically changed the scientific landscape of vector biology56–58. Engineering mosquitoes with enhanced immunity is a potential approach for the control of mosquito-borne diseases59,60. However, over-expression of host genes has not been widely employed due to the lack of efficient and convenient approaches 61. Our previous recombinant AgDNV vector could transduce An. gambiae adults, but transduction efficiency was highly variable. A new smaller vector containing the complete viral UTR sequence, (vUTRAcGFP) had 3-fold higher transduction efficiency in vitro compared to our previous vector (vAgActinGFP). In infected cells, vUTRAcGFP showed more efficient replication than vAgActinGFP. Within paroviruses, the viral genome size significantly affects packaging and replication51,62. Afanasiev et al. suggested that longer DNV genomes were packaged less efficiently than shorter ones51. Other studies demonstrated that a specific region of viral DNA including the 5’ UTR was important for efficient AAV production63. Taken together, these studies suggest shortening the recombinant viral genome and complementing the complete 5’ UTR sequence may synergistically increase transduction efficiency of vUTRAcGFP. In the mosquito, high-levels of GFP expression lasted over fifteen days indicating that AgDNV-based transduction system can efficiently over-express genes for the entire lifespan of the mosquito. By visual observation, there was minimal variation in the intensity detected among individuals.

The most prolific vector in terms of EGFP expression had a relatively long promoter (Actin5C) allowing the insertion of genes approximately 800 bp. We compared the activities of several shorter promoters. In plasmid-transfected cells, the IEx and AcSh promoters showed higher expression than Actin5C (Fig. 4a). Conversely, vUTRAcGFP transduced both the cell line and the mosquito more efficiently than other transducing viruses. The fluorescence intensity in transduced cells and mosquitoes should reflect not only promoter activity but also viral replication. Tullus et al. demonstrated that efficient production of single-stranded AAV DNA that can be packaged into the virion needs a certain minimal size63. AgDNV may also have a limitation on the minimum genome DNA size required for the efficient replication. The polycistronic DNV vector under the control of AcSh promoter, which has a similar size to the wild-type AgDNV, showed higher level of GFP expression than the much shorter vUTRAcShGFP in cell cultures and mosquitoes. Taken together, recombinant AgDNV genome size may be involved in replication efficiency. Future analyses will address the detailed requirements and mechanisms for generation of efficient AgDNV vectors.

By EGFP expression, AgDNV infection was primarily visible in the fat body. The mosquito fat body plays crucial roles in mosquito physiology, including energy storage, metabolism and immunity. This tissue is also proximal to Plasmodium parasites which migrate throughout the hemocoel to invade the salivary gland65,66. The other main target tissue of AgDNV was the ovary. Infection of the ovary may be involved in potential vertical transmission of the virus or inoculation of virus into the larval habitat during oviposition. Although significant transduction was not observed in midgut
and salivary gland (which are important tissues for *Plasmodium* infection) transduction of the fat body and ovary suggest promising strategies to use AgDNV to control *Anopheles*-transmitted parasites. For example, anti-*Plasmodium* peptides such as SM1 or scorpine would be desirable molecules to express as they are short enough to insert into the current AgDNV vector. High expression in the fat body and secretion into the hemolymph has the potential to dramatically inhibit *Plasmodium* 18,20,66,67. Using the polycistronic AgDNV vector multiple anti-*Plasmodium* genes could be expressed simultaneously, leading to a synergistic effect on the parasite. In addition, transduction in the ovaries opens the possibility of using AgDNV to manipulate *Anopheles* reproduction.

In conclusion, we have developed an efficient AgDNV-based overexpression system for *Anopheles gambiae* mosquitoes. Our data suggested that viral genome size and the 5' UTR sequence are important elements for efficient AgDNV infection and replication. These insights may shed light upon other insect parovirus life cycles, which are less well known. Further studies will expand applications to investigation of mosquito biology and paratransgenesis for malaria control.

**Methods**

Cells culture and mosquito rearing. *An. gambiae* MOS55 cells were maintained in Schneider’s medium supplemented with 10% fetal bovine serum at 28°C. *An. gambiae*
mosquitoes (Keele strain) were maintained on 10% sugar solution at 28 °C and 80% humidity with 12/12 h light/dark cycle. The larvae were fed with tetramin fish food. Adults were offered expressed human blood through a membrane feeder for reproduction.

**Plasmid construction.** The pUTR vector was generated based on pBAg19 (infectious clone of AgDNV) by PCR using the forward primer (5′-ATA-TTT-TAA-TCA-ACA-TGT-ATC-ACC-AAA-TAT-A-3′) and reverse primer containing an EcoRV site (5′-GAT-ATC-CAG-TCA-ATT-GGC-CTC-TGG-TCT-TG-3′). The ActinSC promoter-EGFP-SV40 terminator cassette from pAgActinGFP19 was inserted into the EcoRV site in pUTR to make pUTRActGFP. pUTRg7GFP was constructed by inserting the EGFP ORF into pUTR. The copia-SV40E, AcSh-SV40E and Ac2-SV40E cassettes were commercially synthesized (Integrated DNA Technologies) and inserted into the pUTR vector with the EGFP gene. The resulting vectors were referred to as pUTRAcGFP, pUTRShGFP and pUTRg7GFP respectively. To clone the pAcNPVh5 enhancer-IIE1 promoter and IIE1 terminator, pEEx4 (Novagen) was digested with SmaI/ZraI. The resulting vector with the fragment was digested with the EGFP gene. The polycistronic vector pUTRACShgfp-Cherry-GFP-VP was constructed based on pUTRACSh, which contains the short actin promoter and multiple cloning sites. The AgDNV VP gene was amplified from pAgACtv and cloned into the BglII site in pUTRActGFP. The mCherry-T2A-GFP-dT2A sequence was obtained by PCR from pAc5-STATBD1-EcoRV (Addgene) and inserted into the BglII site in pUTRACShVP. Sure2 competent cells (Stratagene) were used for cloning strategies and all plasmids confirmed by direct sequencing.

**Densovirus production.** MOS55 cells at 70% confluence in a 6-well plate were transfected with each recombinant AgDNV plasmid and the helper plasmid pgAgAcTV at a ratio of 2:1 (1.67 μg and 0.83 μg respectively) using Lipofectamine LTX reagent (Life Technologies). At 3 days post transfection, cells were harvested and suspended in PBS. The cell suspension was subjected to freezing-thawing three times and cell debris was removed by centrifugation. The supernatant was used as densovirus samples for DNA extractions.

**Quantification of Densovirus DNA by real-time PCR.** Recombinant DNV samples were treated with TURBO DNase (Ambion) to digest plasmid DNAs. The DNase-resistant viral DNA number was considered as the number of recombinant virions. Total DNA from the densovirus samples or densovirus-infected cell supernatants was extracted using DNEasy kits (Qiagen) according to the manufacturer’s suggested protocol. Quantitative PCR was performed using Quantitect SYBR Green Kit (Qiagen) using a Rotor-Gene Q (Qiagen). The following primer pairs were used for amplification of EGFP gene: EGFP forward: 5′-GTC-TAG-ACC-GAC-GCT-GAG-ATA-TTT-TTC-TCA-3′ and reverse primer containing an EcoRV site (5′-GAT-ATC-CAG-TCA-ATT-GGC-CTC-TGG-TCT-TG-3′). The copy number of recombinant DNV virions. Fluorescence in mosquitoes and dissected tissues was monitored at indicated days post-injection using an Olympus BX-41 microscope. Images were processed using PictureFrame software (Olympus).

**Western Blotting.** Plasmid-transfected MOS55 cells were lysed in Laemmli Sample Buffer (BioRad) containing 2.5% β-mercaptoethanol. Protein samples were separated by SDS-PAGE on 4–15% Mini-PROTEAN™ TGX™ gel (BioRad). EGFP was detected with anti-GFP polyclonal antibody (Santa Cruz Biotechnology) and anti-rabbit IgG HRP-like antibody (Cell Signaling). Signals were developed on Amersham Hyperfilm ECL (GE healthcare) with Amersham ECL Plus Western Blotting Detection Reagents (GE healthcare).

1. Enayati, a. & Hemingway, J. Malaria management: past, present, and future. *Ann. Rev. Entomol.* 55, 589–591 (2010).
2. Mendes, A. M. et al. Conserved mosquito-parasite interactions affect development of *Plasmodium falciparum* in Africa. *PloS Pathog.*, 4, e1000069 (2008).
3. Hemingway, J. & Ranson, H. Insecticide resistance in insect vectors of human disease. *Annu. Rev. Entomol.* 45, 371–391 (2000).
4. Grossman, G. L. et al. Germline transformation of the malaria vector, *Anopheles gambiae*, with the piggyBac transposable element. *Insect Mol. Biol.* 10, 597–604 (2001).
5. Kim, W., Koo, H., Richman, A. & Seeley, D. Ectopic expression of a cecropin transgene in the human malaria vector mosquito *Anopheles gambiae* (Diptera: Culicidae): Effects on susceptibility to *Plasmodium*. *J. Med. Entomol.* 41, 447–455 (2004).
6. Windbichler, N. et al. A synthetic homing endonuclease-based gene drive system in the human malaria mosquito *Anopheles*. *Nature* 473, 212–215 (2011).
7. Bourtis, K. et al. Harnessing mosquito-Wolbachia symbiosis for vector and disease control. *Acta Trop.* 132 Suppl, S150–163 (2014).
8. McGraw, E. & O’Neill, S. Beyond insecticides: new thinking on an ancient problem. *Nat. Rev. Microbiol.* 11, 181–193 (2013).
9. Ricci, I. J. et al. Symbiotic control of mosquito borne disease. *Pathog. Glob. Health* 106, 380–385 (2012).
10. Coutinho-abreu, I. V., Yan, K. & Ramalho-ortigao, M. Transgenesis and paratransgenesis to control insect-borne diseases: Current status and future challenges. *Parasitol. Int.* 59, 1–8 (2010).
11. Minard, G., Mavingui, P. & Moro, C. V. Diversity and function of bacterial microbiota in the mosquito holobiont. *Parasit. Vectors* 6, 146 (2013).
12. Chen, Y., Evans, J. & Feldlaufer, M. Horizontal and vertical transmission of viruses in the Anopheles mosquito (Diptera: Culicidae): perspectives on vector-borne diseases symbiotic control. *PLoS Pathog.* 7, e1002215 (2011).
13. Windbichler, N. et al. A synthetic homing endonuclease-based gene drive system in the human malaria mosquito *Anopheles gambiae*. *Nature* 473, 212–215 (2011).
14. Bourtis, K. et al. Harnessing mosquito-Wolbachia symbiosis for vector and disease control. *Acta Trop.* 132 Suppl, S150–163 (2014).
15. McGraw, E. & O’Neill, S. Beyond insecticides: new thinking on an ancient problem. *Nat. Rev. Microbiol.* 11, 181–193 (2013).
16. Ricci, I. et al. Symbiotic control of mosquito borne disease. *Pathog. Glob. Health* 106, 380–385 (2012).
17. Coutinho-abreu, I. V., Yan, K. & Ramalho-ortigao, M. Transgenesis and paratransgenesis to control insect-borne diseases: Current status and future challenges. *Parasitol. Int.* 59, 1–8 (2010).
18. Michaud, G., Mavingui, P. & Moro, C. V. Diversity and function of bacterial microbiota in the mosquito holobiont. *Parasit. Vectors* 6, 146 (2013).
19. Chen, Y., Evans, J. & Feldlaufer, M. Horizontal and vertical transmission of viruses in the Anopheles mosquito (Diptera: Culicidae): perspectives on vector-borne diseases symbiotic control. *PLoS Pathog.* 7, e1002215 (2011).
20. Fang, W. et al. Development of transgenic fungi that kill human malaria parasites in mosquitoes. Science 331, 1074–1076 (2011).
21. Durvasula, R. V. et al. Genetic transformation of a Corynебacterium symbiont from the Chagas disease vector Triatoma infestans. Exp. Parasitol. 119, 94–98 (2008).
22. Durvasula, R. V. et al. Expression of a functional antibody fragment in the gut of Rhodnius prolixus via transgenic bacterial symbiont Rhodococcus rhodnii. Med. Vet. Entomol. 13, 11511–9 (1999).
23. Durvasula, R. & Gumbs, A. Prevention of insect-borne disease: An approach using transgenic symbiotic bacteria. Proc. Natl. Acad. Sci. 94, 3274–3278 (1997).
24. Favia, G. et al. Bacteria of the genus Asiaa stably associate with Anopheles stephensi, an Asian malarial mosquito vector. Proc. Natl. Acad. Sci. U. S. A. 104, 9047–9051 (2007).
25. Jin, C., Ren, X. & Rasgon, J. L. The virulent Wolbachia strain wMelPop efficiently establishes somatic infections in the malaria vector Anopheles gambiae. Appl. Environ. Microbiol. 75, 3373–3376 (2009).
26. Michel, K. & Kafatos, F. C. Mosquito immunity against Plasmodium. Insect Biochem. Mol. Biol. 35, 677–689 (2005).
27. Blandin, S. a, Marois, E. & Levashina, E. A. Antimalarial responses in Anopheles gambiae: from a complement-like protein to a complement-like pathway. Cell Host Microbe 3, 364–374 (2008).
28. Merkling, S. H. & van Rij, R. P. Beyond RNAi: antiviral defense strategies in Drosophila and mosquito. J. Insect Physiol. 59, 159–170 (2013).
29. Shin, S. W. Transgenesis and reverse genetics of mosquito innate immunity. J. Exp. Biol. 206, 3835–3843 (2003).
30. Fraser, M. J. Insect transgenesis: current applications and future prospects. Annu. Rev. Entomol. 57, 267–289 (2012).
31. Chen, X.-G., Mathur, G. & James, A. A. Gene expression studies in mosquitoes. Adv. Genet. 64, 19–50 (2008).
32. Airenen, K. J. et al. Baculovirus: an insect-derived vector for diverse gene transfer applications. Mol. Ther. 21, 739–749 (2013).
33. Waehler, R., Russell, S. J. & Curiel, D. T. Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet. 8, 573–587 (2007).
34. Amsterdam, A., Varshney, G. K. & Burgess, S. M. Retroviral-mediated Insertional Mutagenesis in Zebrafish. Methods Cell Biol. 104, 59–82 (2011).
35. Dawson, W. O. & Folimonova, S. Y. Virus-based transient expression vectors for therapy. J. Mol. Biol. 239, 659–667 (1994).
36. Bartel, M. A., Weinstein, J. R. & Schaffer, D. V. Directed evolution of novel adenovirus-associated viruses for therapeutic gene delivery. Gene Ther. 19, 694–700 (2012).
37. Maheshri, N., Koerber, J. T., Kaspar, B. K. & Schaffer, D. V. Directed evolution of adenovirus-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24, 198–204 (2006).
38. Carlson, J., Suchman, E. & Buchatsky, L. Densovirus controls for virus and genetic manipulation of mosquitoes. Adv. Virus Res. 68, 368–392 (2006).
39. Li, Y. et al. Genome organization of the densovirus from Bombyx mori (BmDNV-1) and enzyme activity of its capsid. J. Gen. Virol. 82, 2821–2825 (2001).
40. El-Fe`die`re, G., Li, Y., Za´dori, Z., Szelei, J. & Tijssen, P. Genome organization of the cloned infectious genome of the densovirus from Asaia extranea. Virology 191, 2821–2825 (2001).
41. Afanasiev, B. N., Ward, T. W., Beaty, B. J. & Carlson, J. O. Transduction of Aedes aegypti mosquitoes with vectors derived from Aedes denguevirus. Virology 257, 62–72 (1999).
42. Ward, T. W. et al. Aedes aegypti transducing denguevirus pathogenesis and expression in Aedes aegypti and Anopheles gambiae larvae. Insect Mol. Biol. 10, 397–405 (2001).
43. Gu, J.-B., Dong, Y.-Q., Peng, H.-J. & Ren, X.-G. A recombinant AedDNa containing the insect-specific toxin, BmK IT1, displayed an increasing actin 5C proximal promoter. FEBS Lett. 555, 80–86 (2010).
44. Barillas-Mury, C., Han, Y. S., Seeley, D. & Kafatos, F. C. Anopheles gambiae Ag-STAT, a new insect member of the STAT family, is activated in response to bacterial infection. EMBO J. 18, 959–967 (1999).
45. Christophides, G. K. Transgenic mosquitoes and malaria transmission. Cell Microbiol. 7, 325–333 (2005).
46. Dong, Y. et al. Engineered Anopheles immunity to Plasmodium infection. Proc. Natl. Acad. Sci. U. S. A. 99, 11511–11521 (2002).
47. Arrese, E. L. & Soulages, J. L. Insect fat body: energy, metabolism, and regulation. Annu. Rev. Entomol. 55, 207–225 (2010).
48. Dong, Y. et al. Engineered Anopheles immunity to Plasmodium infection. Proc. Natl. Acad. Sci. U. S. A. 99, 11511–11521 (2002).
49. Arrese, E. L. & Soulages, J. L. Insect fat body: energy, metabolism, and regulation. Annu. Rev. Entomol. 55, 207–225 (2010).
50. Christophides, G. K. Transgenic mosquitoes and malaria transmission. Cell Microbiol. 7, 325–333 (2005).
51. Dong, Y. et al. Engineered Anopheles immunity to Plasmodium infection. Proc. Natl. Acad. Sci. U. S. A. 99, 11511–11521 (2002).
52. Cheng, G. et al. An in vivo transfection approach elucidates a role for Aedes aegypti thioster-containing proteins in flavivirus infection. PLoS One 6, e22786 (2011).
53. Wu, Z., Yang, H. & Colosi, P. Effect of genome size on AAV vector packaging. Mol. Ther. 18, 80–86 (2010).
54. Tullis, G. & Shenk, T. Efficient replication of adeno-associated virus type 2 vectors: a cis-acting element outside of the terminal repeats and a minimal size. J. Virol. 74, 11511–11521 (2000).
55. Arrese, E. L. & Soulages, J. L. Insect fat body: energy, metabolism, and regulation. Annu. Rev. Entomol. 55, 207–225 (2010).
56. Barillas-Mury, C., Han, Y. S., Seeley, D. & Kafatos, F. C. Anopheles gambiae Ag-STAT, a new insect member of the STAT family, is activated in response to bacterial infection. EMBO J. 18, 959–967 (1999).
57. Conde, R., Zamudio, F. Z. & Rodi, M. H. Scorpion, an anti-malaria and anti-bacterial agent purified from scorpion venom. FEBS Lett. 471, 165–168 (2001).
58. Ghosh, A. K., Ribolla, P. E. & Jacobs-Lorena, M. Targeting Plasmodium ligands on mosquito salivary glands and midgut with a phage display peptide library. Proc. Natl. Acad. Sci. U. S. A. 98, 13278–13281 (2001).
59. Hughes, G. L., Koga, R., Xue, P., Fukatsu, T. & Rasgon, J. L. Wolbachia infections are virulent and inhibit the human malaria parasite Plasmodium falciparum in Anopheles gambiae. PLoS Pathog. 7, e1002043 (2011).